IDYA

IDEAYA Biosciences, Inc. develops precision medicines targeting hard-to-treat cancers, focusing on uncovering vulnerabilities in these diseases. The company has established a research and development engine aimed at delivering first-in-class targeted therapies and rational combinations for molecularly defined cancers. Its lead investigational candidate, darovasertib, is designed to target the oncogenic driver of uveal melanoma, with a pipeline that includes therapies for various solid tumor indications. IDEAYA operates in the biotechnology sector, serving patients with limited treatment options for aggressive cancers.